Treatment Advances

January 16, 2025

Explore breakthroughs in pediatric AML, from cardiac care to therapies, highlighted at the ASH annual conference.

January 08, 2025

Read specialist insights about managing CLL treatment side effects and third-line therapy options.

December 31, 2024

Review new data presented at ASH about nemtabrutinib, a once-daily, noncovalent, reversible BTK inhibitor. Clinical trials ongoing and recruiting patients.

December 19, 2024

Learn about cellular therapies recommended for people who have TP53-mutant acute myeloid leukemia and myelodysplastic syndromes.

December 05, 2024

FDA reviews belantamab mafodotin for relapsed multiple myeloma, the decision is expected by July 2025.

November 28, 2024

Learn how BRCA gene mutations affect myeloma risk. Learn why genetic testing could be crucial for younger patients and those with family cancer history.

November 25, 2024

Do prior number of treatments and BTK inhibitor response affect CAR T-cell therapy success for MCL? Learn insights from Dr. Manali Kamdar.

November 20, 2024

If you are an adult with relapsed/refractory precursor B-cell ALL, learn how a new FDA-approved CAR T-cell therapy may be a treatment option for you.

November 19, 2024

Learn about revumenib, a newly FDA-approved treatment for relapsed/refractory acute leukemias with the KMT2A gene translocation.

November 19, 2024

Learn insights about how certain treatment combinations and a new scoring system impacted people with low-grade follicular lymphoma.